ISSN 1662-4009 (online)

ey0017.5-2 | Advances in Clinical Practice | ESPEYB17

5.2. Osteogenesis Imperfecta: Skeletal outcomes after bisphosphonate discontinuation at final height

ME Robinson , P Trejo , T Palomo , FH Glorieux , F Rauch

To read the full abstract: J Bone Miner Res. 2019 Dec;34(12):2198–2204.In brief: In Osteogenesis imperfecta (OI), intravenous (IV) cyclical bisphosphonates are often discontinued after cessation of growth in adolescents. This study showed that, four years after discontinuation of treatment, none of the patients sustained new vertebral compression fractures, and the proportion ...